<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714374</url>
  </required_header>
  <id_info>
    <org_study_id>151060</org_study_id>
    <nct_id>NCT02714374</nct_id>
  </id_info>
  <brief_title>Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery</brief_title>
  <official_title>An Open Label, Non-randomized Phase 1b Study to Investigate the Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaitlyn Kelly, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genelux Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the investigational product GL-ONC1.&#xD;
      GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer&#xD;
      drug to destroy cancer cells. Vaccinia virus has been used successfully in the past as&#xD;
      smallpox vaccine in millions of people worldwide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized Phase 1b dose escalation study evaluating the safety&#xD;
      and effect of the oncolytic virus GL-ONC1 administered intravenously, with or without&#xD;
      eculizumab, prior to surgery in patients with advanced solid organ tumors.&#xD;
&#xD;
      GL-ONC1 is a genetically engineered oncolytic vaccinia virus, which disrupts nonessential&#xD;
      genes and expression of the foreign gene expression. Evidence suggest that GL-ONC1 is able to&#xD;
      infect tumor tissue and kill tumor cells.&#xD;
&#xD;
      The goals of this study are to evaluate the safety of GL-ONC1 and to assess the&#xD;
      pharmacokinetics and pharmacodynamics profile of GL-ONC1 in vivo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as defined by CTCAE v4.03.</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of GL-ONC1 within malignant tumors by examination of the resected surgical specimen.</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum concentration (Cmax) of GL-ONC1 in blood after administration</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anti-vaccinia neutralizing antibodies in serum</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Solid Organ Cancers</condition>
  <arm_group>
    <arm_group_label>GL-ONC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3, 5, 7, 8, 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GL-ONC1</intervention_name>
    <description>Dose and Regimen:&#xD;
Single dose group: Cohort 1 dose is 1 × 109 pfu&#xD;
Multiple dose groups:&#xD;
Cohort 2 dose is 1 × 109 pfu × 5 consecutive days&#xD;
Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days&#xD;
Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.&#xD;
Route: GL-ONC1 is delivered as a bolus IV injection.</description>
    <arm_group_label>GL-ONC1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or&#xD;
             aggressive solid organ cancer.&#xD;
&#xD;
          -  Patients must provide written consent for a core needle biopsy sample of tumor tissue&#xD;
             (primary or metastatic).&#xD;
&#xD;
          -  Have evidence of measurable disease (according to RECIST Version 1.1: http://&#xD;
             www.recist.com).&#xD;
&#xD;
          -  Have an ECOG Performance Score of 0 to 2.&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Have adequate organ and marrow function&#xD;
&#xD;
          -  Negative serum pregnancy test for females of childbearing potential.&#xD;
&#xD;
          -  Have negative test result for HIV and Hepatitis B or C testing.&#xD;
&#xD;
          -  Have baseline anti-vaccinia antibody titer &lt; 10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or anticipated use of other investigational agents or marketed anticancer&#xD;
             agent while on study (from the time of enrollment through the time of surgery).&#xD;
&#xD;
          -  Patients who have received chemotherapy or radiotherapy within 4 weeks prior to&#xD;
             entering the study.&#xD;
&#xD;
          -  Small pox vaccination for 4 weeks before study therapy and during study treatment.&#xD;
&#xD;
          -  Have received prior gene therapy or therapy with cytolytic virus of any type.&#xD;
&#xD;
          -  Have clinically significant cardiac disease&#xD;
&#xD;
          -  Oxygen saturation &lt;90% measured by pulse oximetry at rest.&#xD;
&#xD;
          -  Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir,&#xD;
             vaccinia immunoglobulin, imatinib, ST-246) during the course of study.&#xD;
&#xD;
          -  Have known allergy to ovalbumin or other egg products.&#xD;
&#xD;
          -  Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any&#xD;
             unhealed skin wounds or ulcers)&#xD;
&#xD;
          -  Have a history of allergy to iodinated contrast media.&#xD;
&#xD;
          -  Patients with known brain metastases&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaitlyn Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Kaitlyn Kelly, MD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>GL-ONC1</keyword>
  <keyword>Solid Organ Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Oncolytic Virus</keyword>
  <keyword>Soliris</keyword>
  <keyword>Metastatic melanoma</keyword>
  <keyword>Esophageal and gastric adenocarcinoma (Stage III/IV)</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>Gallbladder cancer</keyword>
  <keyword>Colorectal cancer (Stage IV)</keyword>
  <keyword>High-grade mucinous appendix cancer</keyword>
  <keyword>High-grade gastrointestinal neuroendocrine cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>High-grade soft tissue sarcoma</keyword>
  <keyword>Stage III or IV</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

